(Q34486831)

English

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report (English)

1 reference

Europe PubMed Central

2 August 2017

3 references

13 March 2019

24 March 2019

12 November 2019

0 references

pathologic fracture

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

organic compound, having C-P covalent bound

1 reference

12 November 2019

bone density conservation agents

1 reference

16 July 2021

object named as

N Napoli

5

0 references

object named as

C Cooper

8

0 references

author name string

R Rizzoli

1

1 reference

Europe PubMed Central

2 August 2017

K Akesson

2

1 reference

Europe PubMed Central

2 August 2017

M Bouxsein

3

1 reference

Europe PubMed Central

2 August 2017

J A Kanis

4

1 reference

Europe PubMed Central

2 August 2017

S Papapoulos

6

1 reference

Europe PubMed Central

2 August 2017

J-Y Reginster

7

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

18 November 2010

1 reference

Europe PubMed Central

2 August 2017

1 February 2011

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

Osteoporosis International

5 references

Europe PubMed Central

2 August 2017

13 March 2019

24 March 2019

12 November 2019

16 July 2021

22

1 reference

Europe PubMed Central

2 August 2017

2

1 reference

Europe PubMed Central

2 August 2017

373-390

1 reference

Europe PubMed Central

2 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 reference

Europe PubMed Central

16 July 2021

https://scigraph.springernature.com/pub.10.1007/s00198-010-1453-5

0 references

Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Healing of non-displaced fractures produced by fatigue loading of the mouse ulna.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Atraumatic bilateral femur fracture in long-term bisphosphonate use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Case reports: two femoral insufficiency fractures after long-term alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Spectroscopic markers of bone quality in alendronate-treated postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Severely suppressed bone turnover and atypical skeletal fragility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Low-energy femoral shaft fractures associated with alendronate use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Modern therapy for Paget's disease of bone: focus on bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Imaging studies for diagnosing stress and insufficiency fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Unstable intertrochanteric/subtrochanteric fractures of the femur.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Treatment of bone metastases and bone pain with bisphosphonates

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Fragility fractures of the hip and femur: incidence and patient characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Unusual mid-shaft fractures during long-term bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Spontaneous femoral shaft fracture after long-term alendronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Principles of Bone Biomechanics

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

27 October 2018

Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

27 October 2018

Extramedullary fixation of 107 subtrochanteric fractures: a randomized multicenter trial of the Medoff sliding plate versus 3 other screw-plate systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intervention thresholds for osteoporosis in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Looking back: developments in our understanding of the occurrence, aetiology and prognosis of osteoporosis over the last 50 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

More on atypical fractures of the femoral diaphysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric Femoral Insufficiency Fracture in Woman on Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric fractures

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric fractures of the femur

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-010-1453-5

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34486831&oldid=1614830879"